Iradimed (46K) AI Stock Analysis

Iradimed

(Frankfurt:46K)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

High ProfitabilitySustained gross margins near 75–77% and a TTM net margin of roughly 26.8% indicate strong product economics and pricing power. These margins provide substantial capacity to fund research, sales expansion and service infrastructure while absorbing moderate cost or mix pressure.

Negative Factors

Reduced 2026 GuidanceThe reduced full-year outlook signals that execution or timing has been weaker than previously expected, lowering near-term earnings visibility. Repeated guidance pressure could constrain confidence in the growth trajectory and make the company more dependent on successful 3870 ramp execution.

Iradimed (46K) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.02B
Dividend Yield: 1.42%
Average Volume (3M): 3
Price to Earnings (P/E): 42.0
Beta (1Y): 0.26
Revenue Growth: 5.57%
EPS Growth: 7.32%
Country: Germany
Employees: 166
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Iradimed Business Overview & Revenue Model

Company Description

IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongsid...

Iradimed Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:2.01%|Next Earnings Date:Feb 03, 2027

Earnings Call SentimentPositive

The call was strongly positive, supported by record revenue and bookings, rapid adoption of the 3870 pump, strong monitor performance, improving manufacturing efficiencies, robust cash generation and an optimistic 2027 growth outlook. The main challenges were the reduced full-year guidance, the need to moderate the production ramp to protect quality, remaining 3870 production inefficiencies, higher taxes and expenses, and the fact that 3870 disposable pull-through has not yet begun materially.

Positive Updates

Record Quarterly Revenue and Earnings

Third-quarter revenue reached a record $24.2 million, up 14% from $21.2 million in Q3 2025 and up 18% sequentially from $20.5 million in Q2. GAAP diluted earnings per share were $0.51 and non-GAAP diluted earnings per share were $0.55, compared with $0.43 and $0.47, respectively, a year earlier.

Negative Updates

Full-Year Guidance Reduced

The company lowered its full-year 2026 revenue guidance to $91.7 million to $93.2 million from the prior range of $91 million to $96 million. GAAP diluted EPS guidance was reduced to $1.90 to $1.94 from $1.90 to $2.05, and non-GAAP diluted EPS guidance was reduced to $2.06 to $2.10 from $2.06 to $2.21.

Company Guidance

For the fourth quarter, IRadimed expects revenue of $25 million to $26.5 million, GAAP diluted earnings per share of $0.53 to $0.57, non-GAAP diluted earnings per share of $0.57 to $0.61, an effective tax rate of approximately 24% to 25%, gross margin improvement from 76%, and another 50-plus percent increase in 3870 pump output and revenue to about 500 units; for full year 2026, it expects revenue of $91.7 million to $93.2 million, GAAP diluted earnings per share of $1.90 to $1.94, non-GAAP diluted earnings per share of $2.06 to $2.10, approximately $0.6 million of stock-based compensation expense, net of tax, for the fourth quarter and about $2.5 million for the full year; for 2027, production is expected to go from 500 to 560, 570, pump sales are planned at about 2,000 to 2,500 3870s per year, revenue growth is expected to be upper teens of growth, or 15%, 16%, 17% growth, and gross margin could return to historical 77%, 78% and even potentially even better as time goes on.

Iradimed Risk Analysis

Iradimed disclosed 36 risk factors in its most recent earnings report. Iradimed reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Iradimed Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:46K against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	74Outperform	$123.49B	24.28	10.60%	2.88%	9.77%	12.28%
GEHC	71Outperform	$34.62B	20.61	16.13%	0.18%	6.87%	-2.26%
LIVN	69Neutral	$4.35B	23.25	15.41%	―	12.39%	―
INFU	67Neutral	$280.23M	32.93	14.81%	―	2.47%	75.23%
PHG	65Neutral	$26.35B	20.96	10.05%	3.59%	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:46K and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:46K	Iradimed Corp	76.00	2.53	3.44%
INFU	InfuSystem Holdings, Inc.	13.84	3.84	38.40%
PHG	Koninklijke Philips N.V.	27.59	0.41	1.53%
MDT	Medtronic	99.29	11.79	13.48%
LIVN	LivaNova PLC	80.21	29.40	57.86%
GEHC	Ge Healthcare Technologies Inc.	79.55	4.09	5.42%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Iradimed AI Stock Analysis